Bio Insight Bio Reports

AnnJi Reports Promising Phase 1/2a Results for AJ201 in Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and r...

 May 22, 2025 | News

Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC

Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...

 May 21, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

 May 19, 2025 | News

Shanghai Ark Biopharmaceutical Announces Positive Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...

 May 16, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

 May 12, 2025 | News

Connext Completes Phase 1 for CNT201, Eyes Phase 2 Launch and Expansion into Peyronie’s Disease

 Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...

 May 09, 2025 | News

Aroa Biosurgery Surpasses 100 Peer-Reviewed Studies Validating AROA ECM Technology in Wound Care

Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed stud...

 May 05, 2025 | Report

Genmab to Submit sBLA for Epcoritamab-R2 Combination in Relapsed/Refractory Follicular Lymphoma Following Positive Phase 3 Data

--Genmab A/S (Nasdaq: GMAB) announced  its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to t...

 May 05, 2025 | Regulatory

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

 April 28, 2025 | News

Oligonucleotide Market Surges as RNA-Based Therapeutics and CDMO Investments Redefine Global Healthcare Strategies

The global oligonucleotide market, once considered niche, has emerged as a pivotal segment in advanced therapeutics and innovative manufacturing strategies...

 April 24, 2025 | Analysis

Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing

  Cell therapy stands at the forefront of modern medicine, offering transformative potential for treating a wide spectrum of diseas...

 April 22, 2025 | Report

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

 April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

 April 16, 2025 | News

Patent Wars and Patient Lives: Inside Roche vs Natco Over Risdiplam

    In a courtroom packed with legal heavyweights, global pharmaceutical giant F. Hoffmann-La Roche AG faced off against Indian generic manufac...

 April 14, 2025 | Analysis


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close